Klotz U, Arvela P, Rosenkranz B
Clin Pharmacol Ther. 1985 Dec;38(6):652-5. doi: 10.1038/clpt.1985.240.
H2-Receptor antagonists may interfere with the pharmacokinetics of concomitantly administered drugs. Our study was designed to investigate whether cimetidine or ranitidine influence the disposition and sedative effect of midazolam. The effect of single oral doses of 800 mg cimetidine, 300 mg ranitidine, or placebo on the steady-state concentrations of midazolam was examined in a randomized crossover study in eight healthy subjects. A midazolam steady-state concentration was achieved by an intravenous bolus (0.05 mg/kg)-infusion (0.025 mg/kg/hr) technique. Plasma concentrations of midazolam, cimetidine, and ranitidine and the pharmacodynamic response to midazolam (choice reaction time, sedation index) were monitored throughout the 10-hour infusion. Cimetidine significantly increased the mean (+/- SD) steady-state plasma concentration of midazolam from 56.7 +/- 7.8 to 71.3 +/- 19.6 ng/ml (P = 0.004). In contrast, the steady-state midazolam concentration after ranitidine dosing (61.8 +/- 6.8 ng/ml) did not differ significantly from that after placebo. No change in choice reaction time or sedation index was detected after cimetidine or ranitidine dosing. Nevertheless, in contrast to ranitidine, the recently advocated once-daily dosing of cimetidine has a potential for hepatic drug interaction that should be considered before its coadministration with drugs that have a narrow therapeutic index.
H2受体拮抗剂可能会干扰同时服用药物的药代动力学。我们的研究旨在调查西咪替丁或雷尼替丁是否会影响咪达唑仑的处置和镇静效果。在一项针对8名健康受试者的随机交叉研究中,检测了单次口服800毫克西咪替丁、300毫克雷尼替丁或安慰剂对咪达唑仑稳态浓度的影响。通过静脉推注(0.05毫克/千克)-输注(0.025毫克/千克/小时)技术达到咪达唑仑稳态浓度。在整个10小时输注过程中,监测咪达唑仑、西咪替丁和雷尼替丁的血浆浓度以及对咪达唑仑的药效学反应(选择反应时间、镇静指数)。西咪替丁显著提高了咪达唑仑的平均(±标准差)稳态血浆浓度,从56.7±7.8纳克/毫升增至71.3±19.6纳克/毫升(P = 0.004)。相比之下,服用雷尼替丁后的咪达唑仑稳态浓度(61.8±6.8纳克/毫升)与服用安慰剂后无显著差异。服用西咪替丁或雷尼替丁后,未检测到选择反应时间或镇静指数有变化。然而,与雷尼替丁不同,最近提倡的西咪替丁每日一次给药存在肝药物相互作用的可能性,在与治疗指数窄的药物合用前应予以考虑。